MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2δ16 mediated breast tumorigenesis and reverse trastuzumab resistance

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Huynh, Felicia C ^a   Jones, Frank E ^a  

^a Tulane University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 DELTA 16; MICRORNA; MICRORNA 7; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; ISOENZYME; MIRN7 MICRORNA, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER RESISTANCE; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIZATION; COLONY FORMATION; CONTROLLED STUDY; EGFR GENE; ENZYME INACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; BREAST TUMOR; CARCINOGENESIS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CARCINOGENESIS; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MCF-7 CELLS; MICRORNAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SRC-FAMILY KINASES; TRASTUZUMAB;

EID: 84919630737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114419     Document Type: Article

References (32)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
3. Thor AD, Liu S, Edgerton S, Il DM, Kasowitz KM, et al. (2000) Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18: 3230-3239.
4. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, et al. (2009) An oncogenic isoform ofHER2 promotes metastatic breast cancer and trastuzumab resistance Mol Cancer Ther 8: 2152-2162.
5. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, et al. (2010) OncogenicΔD16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31: 2049-2057.
6. Cittelly DM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, et al. (2010) Suppression of miR-342 expression contributes to anti-estrogen resistance in breast tumor cells. Mol Cancer 9: 317.
7. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
8. Pencheva N, Tavazoie SF (2013) Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 15: 546-554.
9. Verghese ET, Hanby AM, Speirs V, Hughes TA (2008) Small is beautiful: microRNAs and breast cancer-where are we now? J Pathol 215: 214-221.
10. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741.
11. Reddy SD, Ohshiro K, Rayala SK, Kumar R (2008) MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 68: 8195-8200.
12. Kong X, Li G, Yuan Y, He Y, Wu X, et al. (2012) MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS ONE 7: e41523.
13. Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, et al. (2013) miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res 73: 1434-1444.
14. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, et al. (2008) The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68: 6387-6395.
15. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
16. Mitra D, Das PM, Jones FE (2010) JUMONJI/ARID1 B (JARID1B) promotes breast tumor cell cycle progression through epigenetic repression of micro RNA let-7e. J Biol Chem 286: 40531-40535.
17. Sridhar J, Sfondouris ME, Bratton MR, Nguyen TL, Townley I, et al. (2014) Identification of quinones asHER2inhibitors for the treatment of trastuzumab resistant breast cancer. Bioorg Med Chem Lett 24: 126-131.
18. Wang H, Tan G, Dong L, Cheng L, Li K, et al. (2012) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE 7: e34210.
19. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, et al. (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496-21507.
20. Barrett A, Madsen B, Copier J, Lu PJ, Cooper L, et al. (2002) PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/ testis antigen? Int J Cancer 101: 581-588.
21. Barrett A, Santangelo S, Tan K, Catchpole S, Roberts K, et al. (2007) Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer 121: 265-275.
22. Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, et al. (2014) JARID1B is a luminal lineagedriving oncogene in breast cancer. Cancer Cell 25: 762-777.
23. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, et al. (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572.
24. Sanchez N, Gallagher M, Lao N, Gallagher C, Clarke C, et al. (2013) MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLoS ONE 8: e65671.
25. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, et al. (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432: 199-205.
26. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6: 209-214.
27. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10: 1507-1517.
28. Playford MP, Schaller MD (2004) The interplay between Src and integrins in normal and tumor biology. Oncogene 23: 7928-7946.
29. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, et al. (2012) Treatment ofHER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9: 16-32.
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody againstHER2 for metastatic breast cancer that overexpressesHER2. N Engl J Med 344: 783-792.
31. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, 2nd, et al. (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160.
32. Zhang S, Huang WC, Li P, Guo H, Poh SB, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17: 461-469.